Germany · Delayed Price · Currency is EUR Evonik Industries AG Earnings Call Transcripts
Fiscal Year 2025
-
Delivered solid 2025 results with EUR 1.9 billion adjusted EBITDA and strong cash flow. 2026 guidance targets stable earnings amid persistent weak demand, cost savings, and a new flexible dividend policy. Regulatory and market changes, especially in methionine and Oxeno, will shape performance.
-
Q3 results were weak, leading to a revised full-year EBITDA guidance of EUR 1.9 billion, but confidence remains in meeting targets due to strong healthcare and Animal Nutrition recovery. Structural cost savings, new plant ramp-ups, and the SYNEQT carve-out are expected to support future performance despite ongoing market challenges.
-
Q2 results were resilient despite macro headwinds, with core segments stable and cost savings underway. Full-year guidance is maintained at the lower end, but achieving it depends on macro improvement and strict cost controls.
-
A new group structure with two segments supports differentiated management and capital allocation, aiming for €1 billion additional EBITDA and 11% ROCE by 2027. Growth is driven by innovation, operational excellence, and targeted investments, with major portfolio steps and disciplined capital allocation.
-
Q1 2025 saw EBITDA and free cash flow rise, with over 50% year-over-year EBITDA growth and record sales. Full-year guidance is confirmed, supported by strong specialty additives and nutrition and care segments, while risks from macroeconomic and trade factors persist.
Fiscal Year 2024
-
Delivered 25% EBITDA growth and strong free cash flow in 2024, with continued earnings growth expected in 2025 driven by cost savings, innovation, and robust segment performance. Market sentiment has improved, and a new segment structure will enhance business steering.
-
Q3 2024 saw sector-leading earnings growth, a 15% EBITDA margin, and strong free cash flow, driven by cost savings and portfolio realignment. Specialty Additives and Silica segments posted robust volume growth, while outlook for 2025 remains positive with continued efficiency focus.
-
Two new flexible epoxy curing agents, Ancamide 2853 and 2865, address market needs for high elongation, toughness, and eco-friendly profiles, with adjustable performance and fast cure times. Both are nonylphenol-free, contain bio content, and are available globally except Europe.
-
Q2 2024 saw sector-leading earnings growth, strong free cash flow, and an upgraded EBITDA outlook. Focus remains on internal optimization, targeted investments, and disciplined capital allocation, with no M&A planned through 2025. Guidance reflects confidence despite macro uncertainties.
-
The AGM highlighted a challenging year with declining sales and a negative net income, but strong free cash flow enabled a stable dividend. Strategic restructuring, cost reductions, and sustainability initiatives were emphasized, alongside new supervisory board members and continued investment in innovation.